Vertex earnings get muted investor response
Source ↗
👁 0
💬 0
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
Comments (0)